SciClone Pharmaceuticals Inc. (NASDAQ:SCLN)’s share price traded up 2.3% during trading on Thursday . The company traded as high as $10.97 and last traded at $10.53, with a volume of 424,423 shares traded. The stock had previously closed at $10.29.

The company has a 50-day moving average price of $13.18 and a 200-day moving average price of $11.22. The company has a market capitalization of $514.06 million and a PE ratio of 19.07.

SciClone Pharmaceuticals (NASDAQ:SCLN) last released its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported $0.19 earnings per share (EPS) for the quarter. The business had revenue of $36.50 million for the quarter, compared to analysts’ expectations of $33.60 million. On average, equities research analysts anticipate that SciClone Pharmaceuticals Inc. will post $0.33 EPS for the current fiscal year.

Several institutional investors have added to or reduced their stakes in the stock. Matarin Capital Management LLC acquired a new position in SciClone Pharmaceuticals during the fourth quarter valued at about $1,600,000. Cornerstone Capital Management Holdings LLC. raised its position in SciClone Pharmaceuticals by 32.3% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 198,570 shares of the specialty pharmaceutical company’s stock valued at $1,827,000 after buying an additional 48,470 shares during the last quarter. Finally, GSA Capital Partners LLP raised its position in SciClone Pharmaceuticals by 20.0% in the fourth quarter. GSA Capital Partners LLP now owns 325,115 shares of the specialty pharmaceutical company’s stock valued at $2,991,000 after buying an additional 54,227 shares during the last quarter.

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.